Category - Developments

Developments

PharmaJet creates two SABs

Closely-held PharmaJet created two scientific advisory boards (SABs) – infectious diseases and oncology – comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping...

April 1, 2024

Developments

AI and precision biologics innovators, iBio and AstralBio, team to build novel best-in-class obesity treatments

iBio (NYSEA:IBIO) entered into a collaboration agreement with AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. Yesterday, iBio announced a concurrent...

March 27, 2024

Developments

LENZ Therapeutics completes merger with Graphite Bio

LENZ Therapeutics (NASDAQ:LENZ) has completed its merger with Graphite Bio in an all-stock transaction. LENZ is advancing its lead assets, LNZ100 and LNZ101, which are both preservative-free, single-use, once-daily eye...

March 22, 2024

Developments

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a non-exclusive collaboration with Siemens Healthineers (XETRA:SHL) aimed at laying the groundwork for Profound to begin marketing a complete therapeutics solution...

February 28, 2024

Developments

iBio sells preclinical PD-1 agonist antibody program to Otsuka

iBio (NYSEA:IBIO) has sold assets related to its early-stage programmed cell death protein 1 (PD-1 ) agonist program to Otsuka Pharmaceutical. Under the terms of the accord, iBio received an upfront payment of $1.0...

February 27, 2024

Developments

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform

IntelGenx (TSX:IGX; OTCQB:IGXT) announced positive results from a proof-of-concept study, conducted through a research collaboration with the University Prince Edward Island (UPEI), to assess the palatability, owner...

February 5, 2024

Developments

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

BioRestorative Therapies (NASDAQ:BRTX) announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society’s 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded...

February 5, 2024

Developments

Japan Patent Office issues decision to grant patent for Anixa’s ovarian cancer vaccine

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application covering the company’s ovarian cancer...

January 23, 2024

Developments

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

In a 13G filed with the SEC today, accomplished businessman and founder of namesake transportation company Daseke (NADAQ:DSKE), Don Daseke, disclosed he has taken a 5.2% ownership stake in Profound Medical (NASDAQ:PROF)...

January 12, 2024

Developments

Sigyn outlines 2023 achievements, 2024 outlook

In a letter to shareholders to Sigyn Therapeutics’ (OTCQB:SIGY) shareholders, Jim Joyce, chairman and CEO, said as a small organization operating in a world with short-term expectations, the company has “not wavered...

January 8, 2024

Category - Developments

PharmaJet creates two SABs

AI and precision biologics innovators, iBio and AstralBio, team to build novel best-in-class obesity treatments

LENZ Therapeutics completes merger with Graphite Bio

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

iBio sells preclinical PD-1 agonist antibody program to Otsuka

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

Japan Patent Office issues decision to grant patent for Anixa’s ovarian cancer vaccine

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

Sigyn outlines 2023 achievements, 2024 outlook

General

More